AIM ImmunoTech (UK) Performance
| 0A4Y Stock | 0.20 0.01 4.76% |
The firm shows a Beta (market volatility) of 0.55, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, AIM ImmunoTech's returns are expected to increase less than the market. However, during the bear market, the loss of holding AIM ImmunoTech is expected to be smaller as well. At this point, AIM ImmunoTech has a negative expected return of -0.23%. Please make sure to confirm AIM ImmunoTech's variance, jensen alpha, and the relationship between the standard deviation and information ratio , to decide if AIM ImmunoTech performance from the past will be repeated in the future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days AIM ImmunoTech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 0.022727:1 | Last Split Date 2019-06-11 |
1 | Exploring AIM ImmunoTechs Earnings Expectations - Benzinga | 11/07/2024 |
2 | AIM ImmunoTech shifts director pay to stock for cash conservation - Investing.com | 11/27/2024 |
3 | AIM ImmunoTech says Glass Lewis recommends shareholders vote for nominees - TipRanks | 12/10/2024 |
4 | Aim Immunotech director William Mitchell sells 883 in stock - Investing.com | 12/20/2024 |
5 | AIM ImmunoTech Upgraded to Strong Buy What Does It Mean for the Stock - Yahoo Finance | 01/17/2025 |
AIM |
AIM ImmunoTech Relative Risk vs. Return Landscape
If you would invest 26.00 in AIM ImmunoTech on November 2, 2024 and sell it today you would lose (6.00) from holding AIM ImmunoTech or give up 23.08% of portfolio value over 90 days. AIM ImmunoTech is generating negative expected returns and assumes 6.0934% volatility on return distribution over the 90 days horizon. Simply put, 54% of stocks are less volatile than AIM, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
AIM ImmunoTech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AIM ImmunoTech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AIM ImmunoTech, and traders can use it to determine the average amount a AIM ImmunoTech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0382
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 0A4Y |
Estimated Market Risk
| 6.09 actual daily | 54 54% of assets are less volatile |
Expected Return
| -0.23 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average AIM ImmunoTech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AIM ImmunoTech by adding AIM ImmunoTech to a well-diversified portfolio.
AIM ImmunoTech Fundamentals Growth
AIM Stock prices reflect investors' perceptions of the future prospects and financial health of AIM ImmunoTech, and AIM ImmunoTech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AIM Stock performance.
| Return On Equity | -1.55 | ||||
| Return On Asset | -0.8 | ||||
| Operating Margin | (73.88) % | ||||
| Current Valuation | 6.55 M | ||||
| Revenue | 201 K | ||||
| Gross Profit | 143 K | ||||
| EBITDA | (31.36 M) | ||||
| Net Income | (19.45 M) | ||||
| Book Value Per Share | 0.19 X | ||||
| Earnings Per Share | (0.40) X | ||||
| Retained Earnings | (361.1 M) |
About AIM ImmunoTech Performance
Assessing AIM ImmunoTech's fundamental ratios provides investors with valuable insights into AIM ImmunoTech's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the AIM ImmunoTech is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
AIM ImmunoTech is entity of United Kingdom. It is traded as Stock on LSE exchange.Things to note about AIM ImmunoTech performance evaluation
Checking the ongoing alerts about AIM ImmunoTech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AIM ImmunoTech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AIM ImmunoTech generated a negative expected return over the last 90 days | |
| AIM ImmunoTech has high historical volatility and very poor performance | |
| AIM ImmunoTech has some characteristics of a very speculative penny stock | |
| AIM ImmunoTech has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 201 K. Net Loss for the year was (19.45 M) with profit before overhead, payroll, taxes, and interest of 143 K. | |
| Latest headline from news.google.com: AIM ImmunoTech Upgraded to Strong Buy What Does It Mean for the Stock - Yahoo Finance |
- Analyzing AIM ImmunoTech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AIM ImmunoTech's stock is overvalued or undervalued compared to its peers.
- Examining AIM ImmunoTech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AIM ImmunoTech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AIM ImmunoTech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AIM ImmunoTech's stock. These opinions can provide insight into AIM ImmunoTech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for AIM Stock Analysis
When running AIM ImmunoTech's price analysis, check to measure AIM ImmunoTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AIM ImmunoTech is operating at the current time. Most of AIM ImmunoTech's value examination focuses on studying past and present price action to predict the probability of AIM ImmunoTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AIM ImmunoTech's price. Additionally, you may evaluate how the addition of AIM ImmunoTech to your portfolios can decrease your overall portfolio volatility.